

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/051895 A1

(51) International Patent Classification⁷: **C07C 237/20**,
C07D 295/02, C07C 237/24, 271/24, 323/29, 255/50,
C07D 319/18, 313/08, 307/79, 207/09, 333/08, A61P
9/12, A61K 31/165, 31/325, 31/44

(21) International Application Number:
PCT/EP2004/013412

(22) International Filing Date:
25 November 2004 (25.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/525,374 26 November 2003 (26.11.2003) US

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH**
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant and

(72) Inventor (for all designated States except AT, US): **NO-
VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAESCHLIN,**
Daniel, Kaspar [CH/CH]; In der Schappe 141, CH-4144
Arlesheim (CH). **MAIBAUM, Jürgen, Klaus** [DE/DE];
Lütemannsweg 14/1, 79576 Weil-Haltingen (DE). **SELL-
NER, Holger** [DE/CH]; Keltenstr. 37, CH-4106 Therwil
(CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellect-
tual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ORGANIC COMPOUNDS



(I)

(57) Abstract: Disclosed are δ-amino-γ-hy-
droxy-ω-aryl-alkanoic acid amide compounds of
formula (I) and the salts thereof, having renin-inhibiting
properties. Also disclosed are pharmaceutical
compositions comprising these compounds and methods
of administering them for the treatment of hypertension,
atherosclerosis, unstable coronary syndrome, congestive
heart failure, cardiac hypertrophy, cardiac fibrosis,
cardiomyopathy postinfarction, unstable coronary
syndrome, diastolic dysfunction, chronic kidney disease,
hepatic fibrosis, complications resulting from diabetes,

such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised
intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia,
anxiety states and cognitive disorders.

WO 2005/051895 A1